ORHB Stock Crashes 98.89% on Pink Sheets, Surgical Software Firm Faces Delisting Risk

ORHB stock has collapsed to historic lows, trading at just $0.0001 USD on the Pink Sheets (PNK) exchange. The surgical software company ORHub, Inc. experienced a devastating 98.89% decline from its previous close of $0.009, marking one of the most severe losses in recent trading. Based in Phoenix, Arizona, ORHub provides cloud-based surgical data analytics solutions for hospitals and medical device vendors. The company’s market capitalization has shrunk to just $13,750, reflecting severe financial distress. With negative earnings, mounting losses, and a “Sell” rating from analysts, ORHB stock represents an extreme risk for investors.

ORHB Stock Price Collapse and Market Metrics

ORHB stock hit rock bottom on March 5, 2025, trading at $0.0001 with a staggering -98.89% single-day loss. The stock’s 50-day moving average sits at $0.0007, while the 200-day average is $0.000272, showing consistent downward pressure. Volume surged to 32,000 shares, significantly above the average of 7,428, indicating panic selling.

The year-to-date performance reveals deeper problems. ORHB peaked at $0.01 annually but has since cratered to its floor price. With 137.5 million shares outstanding and a market cap of only $13,750, the company is essentially worthless by traditional valuation standards. The enterprise value stands at $9.17 million, creating massive disconnect between debt obligations and market value. Track ORHB on Meyka for real-time updates on this distressed security.

Financial Distress and Negative Fundamentals

ORHub’s financial metrics paint a dire picture of operational failure. The company reports negative earnings per share of -$0.01 with a net profit margin of -41.2%, meaning every dollar of revenue generates significant losses. Operating margins are equally catastrophic at -37.43%, indicating the core business cannot sustain itself.

Cash flow metrics are deeply negative. Operating cash flow per share is -$0.0017, while free cash flow per share mirrors this at -$0.0017. The current ratio of 0.023 reveals severe liquidity problems, with current liabilities far exceeding current assets. Working capital deficit reaches -$11.07 million, suggesting the company cannot meet short-term obligations. Return on assets is -7.1%, confirming management’s inability to generate returns from company resources.

Analyst Rating and Investment Risk Assessment

Meyka AI rates ORHB with a grade of B and a “Hold” suggestion, based on a score of 62.66. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. However, the company’s official rating is “Sell” with a score of just 2 out of 10. The rating details show “Strong Sell” recommendations across DCF valuation, return on assets, debt-to-equity, and price-to-earnings metrics.

The only bright spot is the ROE score of 5 with a “Strong Buy” recommendation, though this is misleading given negative equity. These grades are not guaranteed and we are not financial advisors. The overwhelming negative signals suggest extreme caution for any investor considering this security.

Market Sentiment and Trading Activity

Trading activity reveals institutional and retail abandonment of ORHB stock. The relative volume of 4.31 shows trading activity above normal levels, driven by forced liquidations rather than genuine buying interest. The RSI of 44.4 indicates oversold conditions, yet the stock continues declining, suggesting capitulation selling.

The ADX reading of 46.2 signals a strong downtrend with conviction. Williams %R at -100 confirms extreme oversold status with no recovery momentum. The Money Flow Index of 52.24 shows neutral sentiment, but this masks the underlying panic. Days sales outstanding of 198.77 days indicates collection problems, while the company struggles to convert receivables into cash. This combination suggests ongoing liquidation pressure with minimal institutional support.

Final Thoughts

ORHB stock represents an extreme case of financial collapse in the healthcare software sector. The 98.89% crash to $0.0001 reflects fundamental business failure, not temporary market weakness. Negative earnings, massive cash burn, liquidity crisis, and overwhelming debt create a perfect storm for shareholders. The company’s market cap of just $13,750 suggests potential delisting from the Pink Sheets exchange. With a “Sell” rating and negative fundamentals across every metric, ORHB stock offers no recovery catalyst visible on the horizon. Investors should avoid this security entirely and focus capital on companies with sustainable business models and positive cash flow generation.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.